<DOC>
	<DOC>NCT00663741</DOC>
	<brief_summary>This study is to investigate safety, pharmacokinetics and preliminary efficacy profile of sorafenib in combination with S-1 plus cisplatin in Asian patients with unresectable / recurrent gastric cancer.</brief_summary>
	<brief_title>Sorafenib Gastric Cancer Asian Phase I Study</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histological or cytological confirmation of the primary unresectable or recurrent gastric cancer (both with and without measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) are allowed). Peritoneal dissemination without ascites is allowed. No prior systemic anticancer therapy including chemotherapy, immunotherapy, targeted agents or experimental therapies for advanced disease Prior adjuvant therapy/neo adjuvant therapy is allowed if recurrence occurred 6 months after completion of these therapies Age &gt;/= 18 years and &lt; 75 years Known brain metastasis, spinal cord compression or meningeal carcinomatosis. Clinically relevant ascites Concurrent cancer that is distinct in primary site or histology from gastric cancer Any condition that impairs patient's ability to swallow whole pills</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Unresectable / recurrent gastric cancer</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>S-1</keyword>
	<keyword>Gastric</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>CDDP</keyword>
</DOC>